Evidence map›Paper›PMID 41871810›Full record

ArticleThe Journal of biological chemistry2026

Engineering high-fidelity tapasin variants to enhance MHC-I antigen presentation.

Molly C Erdman, Kaya Epstein, Daniel Hwang, Radia M M Khan, Shirley M Sun, Nikolaos G Sgourakis

Abstract read
In one paragraph

Article in The Journal of biological chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Molly C ErdmanCenter for Computational and Genomic Medicine, Department of Pathology and Laboratory Medicine, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Kaya EpsteinCenter for Computational and Genomic Medicine, Department of Pathology and Laboratory Medicine, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA; Cancer Biology Graduate Group, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Daniel HwangCenter for Computational and Genomic Medicine, Department of Pathology and Laboratory Medicine, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA; Department of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Radia M M KhanCenter for Computational and Genomic Medicine, Department of Pathology and Laboratory Medicine, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA; Bioengineering Graduate Group, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Shirley M SunCenter for Computational and Genomic Medicine, Department of Pathology and Laboratory Medicine, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA; Cancer Biology Graduate Group, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Nikolaos G SgourakisCenter for Computational and Genomic Medicine, Department of Pathology and Laboratory Medicine, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA; Department of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Electronic address: nikolaos.sgourakis@pennmedicine.upenn.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human leukocyte antigen (HLA) proteins are extremely polymorphic, with different allotypes exhibiting a wide range of dependencies on the chaperone tapasin for peptide loading, expression, and stability at the cell surface. Given its central role in antigen processing, tapasin is frequently downregulated across viral infections and cancers, impairing antigen presentation and hindering the identification of therapeutically relevant peptide antigens. We hypothesized that elucidating the mutational tolerance of tapasin surfaces, which mediate interactions with polymorphic HLA residues, can provide a means for fine-tuning its chaperoning function and reveal mechanistic epitopes that underlie its function. Using two complementary deep mutational scanning screens, we systematically mapped the tapasin/HLA-A∗02:01 interaction landscape, highlighting key regions involved in HLA-I assembly and repertoire optimization. We engineered two high-fidelity tapasin variants, tapasin-YTY and tapasin-I2, and show that these variants can increase cell surface HLA expression on a wild-type (WT) tapasin-deficient background by up to 50% and improve peptide-loading function across multiple HLA-A∗ allotypes. Our findings establish scanning mutagenesis as a general approach for fine-tuning chaperone interactions with HLA molecules to enhance antigen presentation in immunologically impaired settings.

Indexed as

Antigen PresentationHistocompatibility Antigens Class IMembrane Transport ProteinsProtein EngineeringHumansHistocompatibility Antigens Class IMembrane Transport Proteinstapasinantigen processing and presentationchaperonedeep mutational scanning (DMS)functional genomicshigh-throughput screening (HTS)major histocompatibility complex (MHC)neuroblastomaprotein engineering

Identifiers

PMID41871810
PMCPMC13125989

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.